These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36805834)

  • 1. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
    Karbalaee M; Jameie M; Amanollahi M; TaghaviZanjani F; Parsaei M; Basti FA; Mokhtari S; Moradi K; Ardakani MK; Akhondzadeh S
    Schizophr Res; 2023 Apr; 254():92-98. PubMed ID: 36805834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
    Salehi A; Namaei P; TaghaviZanjani F; Bagheri S; Moradi K; Khodaei Ardakani MR; Akhondzadeh S
    Psychiatry Res; 2022 Oct; 316():114737. PubMed ID: 35917650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial.
    Shamabadi A; Fattollahzadeh-Noor S; Fallahpour B; A Basti F; Khodaei Ardakani MR; Akhondzadeh S
    Psychopharmacology (Berl); 2023 Dec; 240(12):2631-2640. PubMed ID: 37697164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
    Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
    Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
    J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Khoaie-Ardakani MR; Shahmoradi Z; Alavi AR; Afarideh M; Shalbafan MR; Ghazizadeh-Hashemi M; Akhondzadeh S
    Psychiatry Res; 2018 Apr; 262():94-101. PubMed ID: 29427913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
    Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY
    J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
    Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
    Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study.
    Rezaei F; Mesgarpour B; Jeddian A; Zeionoddini A; Mohammadinejad P; Salardini E; Shahriari M; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28421639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
    Samaei A; Moradi K; Bagheri S; Ashraf-Ganjouei A; Alikhani R; Mousavi SB; Rezaei F; Akhondzadeh S
    Int J Neuropsychopharmacol; 2020 Dec; 23(12):775-782. PubMed ID: 33372679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
    Noroozian M; Ghasemi S; Hosseini SM; Modabbernia A; Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Rezaei F; Salehi B; Ashrafi M; Yekehtaz H; Tabrizi M; Akhondzadeh S
    Psychopharmacology (Berl); 2013 Aug; 228(4):595-602. PubMed ID: 23515583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.